About Noelin-3
Noelin-3 (OLFM3) is a protein
from Homo sapiens identified by UniProt accession
Q96PB7, 478 residues long.
MolForge cross-references it against 0 known binders and
34 disease associations.
Target properties
| Protein name | Noelin-3 |
|---|
| UniProt accession | Q96PB7 |
|---|
| Gene | OLFM3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 478 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (34)
Diseases linked to this target (Open Targets).
- age at menarche · score 0.38
- gut microbiome measurement · score 0.31
- body height · score 0.30
- leukocyte count · score 0.21
- Tinnitus · score 0.16
- body fat percentage · score 0.16
- fat body mass · score 0.07
- self reported educational attainment · score 0.06
- astrocytoma · score 0.04
- central nervous system cancer · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q96PB7-F1 | alphafold | PREDICTED | 78.46 | — |
Amino-acid sequence (478 residues)
MSPPLLKLGA VLSTMAMISN WMSQTLPSLV GLNTTRLSTP DTLTQISPKE GWQVYSSAQD PDGRCICTVV APEQNLCSRD AKSRQLRQLL EKVQNMSQSI EVLNLRTQRD FQYVLKMETQ MKGLKAKFRQ IEDDRKTLMT KHFQELKEKM DELLPLIPVL EQYKTDAKLI TQFKEEIRNL SAVLTGIQEE IGAYDYEELH QRVLSLETRL RDCMKKLTCG KLMKITGPVT VKTSGTRFGA WMTDPLASEK NNRVWYMDSY TNNKIVREYK SIADFVSGAE SRTYNLPFKW AGTNHVVYNG SLYFNKYQSN IIIKYSFDMG RVLAQRSLEY AGFHNVYPYT WGGFSDIDLM ADEIGLWAVY ATNQNAGNIV ISQLNQDTLE VMKSWSTGYP KRSAGESFMI CGTLYVTNSH LTGAKVYYSY STKTSTYEYT DIPFHNQYFH ISMLDYNARD RALYAWNNGH QVLFNVTLFH IIKTEDDT
Explore Noelin-3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets